These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 25319502)

  • 1. Chimeric antigen receptor T cells for ALL.
    Amrolia PJ; Pule M
    Lancet; 2015 Feb; 385(9967):488-90. PubMed ID: 25319502
    [No Abstract]   [Full Text] [Related]  

  • 2. Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
    Hill JA; Li D; Hay KA; Green ML; Cherian S; Chen X; Riddell SR; Maloney DG; Boeckh M; Turtle CJ
    Blood; 2018 Jan; 131(1):121-130. PubMed ID: 29038338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.
    Kebriaei P; Singh H; Huls MH; Figliola MJ; Bassett R; Olivares S; Jena B; Dawson MJ; Kumaresan PR; Su S; Maiti S; Dai J; Moriarity B; Forget MA; Senyukov V; Orozco A; Liu T; McCarty J; Jackson RN; Moyes JS; Rondon G; Qazilbash M; Ciurea S; Alousi A; Nieto Y; Rezvani K; Marin D; Popat U; Hosing C; Shpall EJ; Kantarjian H; Keating M; Wierda W; Do KA; Largaespada DA; Lee DA; Hackett PB; Champlin RE; Cooper LJ
    J Clin Invest; 2016 Sep; 126(9):3363-76. PubMed ID: 27482888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment of lymphoblastic leukemia with CD19-specific modified chimeric antigen receptor T cells].
    Li HH; Zhu P; Wu XQ; Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1753-6. PubMed ID: 25543510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Advances of treatment study on acute lymphoblastic leukemia with chimeric antigen receptor modified T cells].
    Weng WW; Tang YM
    Zhonghua Er Ke Za Zhi; 2019 Aug; 57(8):643-646. PubMed ID: 31352754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Coverage Analysis of CAR-T Therapies - Policy, Evidence, and Payment.
    Bach PB
    N Engl J Med; 2018 Oct; 379(15):1396-1398. PubMed ID: 30110578
    [No Abstract]   [Full Text] [Related]  

  • 7. Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia.
    Cai B; Guo M; Wang Y; Zhang Y; Yang J; Guo Y; Dai H; Yu C; Sun Q; Qiao J; Hu K; Zuo H; Dong Z; Zhang Z; Feng M; Li B; Sun Y; Liu T; Liu Z; Wang Y; Huang Y; Yao B; Han W; Ai H
    J Hematol Oncol; 2016 Nov; 9(1):131. PubMed ID: 27887660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
    Wang M
    Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
    [No Abstract]   [Full Text] [Related]  

  • 9. Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.
    Brower V
    J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25838441
    [No Abstract]   [Full Text] [Related]  

  • 10. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
    Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
    Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chimeric Antigen Receptor (CAR) T-cell therapy; a promising outlook for refractory malignancies - Letter to the Editor.
    Haider SA; Tariq SM; Hasan M
    J Pak Med Assoc; 2018 Sep; 68(9):1288. PubMed ID: 30317285
    [No Abstract]   [Full Text] [Related]  

  • 12. CAR T-cells merge into the fast lane of cancer care.
    Frey NV; Porter DL
    Am J Hematol; 2016 Jan; 91(1):146-50. PubMed ID: 26574400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric Antigen Receptor T Cell Therapy Targeting CD19-Positive Leukemia and Lymphoma in the Context of Stem Cell Transplantation.
    Schubert ML; Hückelhoven A; Hoffmann JM; Schmitt A; Wuchter P; Sellner L; Hofmann S; Ho AD; Dreger P; Schmitt M
    Hum Gene Ther; 2016 Oct; 27(10):758-771. PubMed ID: 27479233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-Cell Therapy Has Lasting Effects.
    Cancer Discov; 2016 Feb; 6(2):113. PubMed ID: 26719386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis.
    Zhang T; Cao L; Xie J; Shi N; Zhang Z; Luo Z; Yue D; Zhang Z; Wang L; Han W; Xu Z; Chen H; Zhang Y
    Oncotarget; 2015 Oct; 6(32):33961-71. PubMed ID: 26376680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tragedy, Perseverance, and Chance - The Story of CAR-T Therapy.
    Rosenbaum L
    N Engl J Med; 2017 Oct; 377(14):1313-1315. PubMed ID: 28902570
    [No Abstract]   [Full Text] [Related]  

  • 17. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
    Chen R; Song XT; Chen B
    Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf.
    Ruella M; Kenderian SS
    BioDrugs; 2017 Dec; 31(6):473-481. PubMed ID: 29143249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy: CAR-modified T cells targeting CD19-curing the incurable.
    Hutchinson L
    Nat Rev Clin Oncol; 2014 Dec; 11(12):683. PubMed ID: 25348787
    [No Abstract]   [Full Text] [Related]  

  • 20. CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
    Singh N; Frey NV; Grupp SA; Maude SL
    Curr Treat Options Oncol; 2016 Jun; 17(6):28. PubMed ID: 27098534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.